Calcitonin Gene-Related Peptide

Calcitonin gene-related peptide. A 37-amino acid peptide derived from the calcitonin gene. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.

Also Known As:

Networked: 1883 relevant articles (44 outcomes, 233 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Edvinsson, Lars: 27 articles (01/2016 - 01/2002)
2.	Ohtori, Seiji: 26 articles (12/2015 - 09/2003)
3.	Takahashi, Kazuhisa: 25 articles (12/2015 - 04/2004)
4.	Goadsby, Peter J: 20 articles (10/2015 - 11/2002)
5.	Russo, Andrew F: 18 articles (06/2015 - 04/2002)
6.	Aoki, Yasuchika: 17 articles (10/2015 - 04/2004)
7.	Inoue, Gen: 17 articles (10/2015 - 10/2006)
8.	Li, Yuan-Jian: 17 articles (03/2013 - 05/2002)
9.	Orita, Sumihisa: 16 articles (10/2015 - 10/2009)
10.	Olesen, J: 16 articles (01/2012 - 05/2000)

Related Diseases

1.	Migraine Disorders (Migraine) 09/01/2014 - "These results provide preliminary evidence that LY2951742 might be beneficial in migraine prevention and provide support for the role of calcitonin gene-related peptide in the pathogenesis of migraine. " 11/22/2002 - "It is proposed that clinically effective anti-migraine compounds, such as 5-HT(1B/1D) agonists, have actions that include inhibiting calcitonin gene-related peptide (CGRP) release from trigeminal nerves. " 11/01/2014 - "Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial." 09/01/2014 - "Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study." 09/01/2014 - "We assessed the safety and efficacy of LY2951742, a fully humanised monoclonal antibody to calcitonin gene-related peptide, for migraine prevention. "
2.	Headache (Headaches) 01/01/2011 - "Clinical and experimental studies have revealed a central role of calcitonin gene-related peptide (CGRP) in primary headaches. " 07/01/2012 - "Calcitonin gene-related peptide (CGRP) is regarded as a key mediator in the generation of primary headaches. " 01/01/2011 - "The trigeminal ganglion and calcitonin gene-related peptide (CGRP) are crucial components in the pathophysiology of primary headaches. " 01/01/2011 - "Clinical and experimental results have revealed a fundamental role of calcitonin gene-related peptide (CGRP) in primary headaches. " 10/26/2010 - "Calcitonin gene-related peptide (CGRP) plays a fundamental role in the pathophysiology of neurovascular headaches. "
3.	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 10/27/2000 - "We sought to determine whether adenovirus-mediated gene transfer in vivo of calcitonin gene-related peptide (CGRP), a potent vasodilator, ameliorates cerebral vasoconstriction after experimental subarachnoid hemorrhage (SAH). " 11/01/1991 - "The authors propose that the marked decrease of calcitonin gene-related peptide immunoreactivity in the perivascular nerves, observed after experimental subarachnoid hemorrhage, is due to compensatory secretion of the peptide." 10/27/2000 - "Gene transfer of calcitonin gene-related peptide prevents vasoconstriction after subarachnoid hemorrhage." 09/15/1995 - "The neuroprotective effect of calcitonin gene-related peptide following subarachnoid hemorrhage. " 09/01/1995 - "Effects of subarachnoid hemorrhage on vascular responses to calcitonin gene-related peptide and its related second messengers."
4.	Heart Failure 08/10/2013 - "Alpha-calcitonin gene-related peptide is protective against pressure overload-induced heart failure." 03/01/1990 - "Improved cardiac performance with human calcitonin gene related peptide in patients with congestive heart failure." 01/01/1994 - "Some studies have indicated that plasma calcitonin gene-related peptide (CGRP) increases in congestive heart failure (CHF). " 12/01/1992 - "Calcitonin gene-related peptide: a haemodynamic study of a novel vasodilator in patients with severe chronic heart failure." 11/01/1992 - "To investigate the role of calcitonin gene-related peptide (CGRP) in cardiac failure, a sensitive and specific radioimmunoassay was developed to study plasma levels of CGRP in 37 normal subjects and 41 patients with heart failure (HF). "
5.	Ischemia 03/01/2011 - "The protective effects of calcitonin gene-related peptide on gastric mucosa injury of gastric ischemia reperfusion in rats." 08/01/1995 - "A study was undertaken to determine the effects of the topical vasodilator calcitonin gene-related peptide on the microcirculation of flaps after mechanically induced ischemia. " 01/01/1992 - "The effect of calcitonin-gene-related peptide on acute ischemia-reperfusion renal injury: ultrastructural and membrane lipid peroxidation studies." 02/01/2012 - "Intermedin (IMD)(1-53) is a novel member of the calcitonin gene-related peptide superfamily and has potent cardioprotective effects against myocardial injury induced by ischemia-reperfusion (I/R). " 02/01/2011 - "Calcitonin gene-related peptide facilitates revascularization during hindlimb ischemia in mice."

Related Drugs and Biologics

1.	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)
2.	Substance P
3.	N- (6- (2,3- difluorophenyl)- 2- oxo- 1- (2,2,2- trifluoroethyl)azepan- 3- yl)- 4- (2- oxo- 2,3- dihydro- 1H- imidazo(4,5- b)pyridin- 1- yl)piperidine- 1- carboxamide
4.	Neuropeptides
5.	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))
6.	calcitonin gene-related peptide (8-37)
7.	Vasodilator Agents (Vasodilators)
8.	olcegepant
9.	Neuropeptide Y
10.	Capsaicin (Zostrix)

Related Therapies and Procedures

1.	Denervation
2.	Radiotherapy
3.	Aftercare (After-Treatment)
4.	Anesthesia
5.	Axotomy